Chase Therapeutics’ drug development pipeline currently holds promising examples of our unique approach to products targeting both the palliative and neuroprotective treatment of Parkinson’s disease and related movement and cognitive disorders, as well as for the symptomatic relief of major depressive episodes. These novel compounds arise from the creative efforts of the company team and are protected by a robust estate of patents pending in the U.S. and abroad.
Our lead compounds, CTC-413 for the symptomatic and neuroprotective treatment of Parkinson’s disease and related disorders and CTC-501 for the symptomatic treatment of depression, are currently entering Phase 2 clinical evaluation. These novel products employ innovative approaches to disease modification for Parkinson’s disease and symptom relief in the case of major depressive disorder. In addition, a bioassay to diagnose Parkinson’s disease and related disorders as well as to serve as an immediate response outcome measure especially for use in clinical trials of potentially neuroprotective treatments is also under development.
